

**Isoray, Inc. and Subsidiaries**  
**Consolidated Balance Sheets**  
(In thousands, except shares)

	<u>June 30,</u> <u>2020</u>	<u>June 30,</u> <u>2019</u>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 2,392	\$ 5,326
Accounts receivable, net	2,044	1,154
Inventory	645	530
Prepaid expenses and other current assets	426	305
	<hr/>	<hr/>
Total current assets	5,507	7,315
Property and equipment, net	1,735	1,609
Right of use asset, net	1,001	-
Restricted cash	181	181
Inventory, non-current	137	155
Other assets, net of accumulated amortization	138	162
	<hr/>	<hr/>
Total assets	<u>\$ 8,699</u>	<u>\$ 9,422</u>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable and accrued expenses	\$ 654	\$ 683
Lease liability	236	-
Accrued protocol expense	35	133
Accrued radioactive waste disposal	94	74
Accrued payroll and related taxes	352	89
Accrued vacation	204	142
	<hr/>	<hr/>
Total current liabilities	1,575	1,121
Non-current liabilities:		
Lease liability, non-current	769	-
Accrued payroll and related taxes, non-current	55	-
Asset retirement obligation	577	621
	<hr/>	<hr/>
Total liabilities	2,976	1,742
Commitments and contingencies		
Shareholders' equity:		
Preferred stock, \$.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding	-	-
Common stock, \$.001 par value; 200,000,000 shares authorized; 68,897,779 and 67,338,047 shares issued and outstanding	69	67
Additional paid-in capital	93,592	92,105
Accumulated deficit	(87,938)	(84,492)
	<hr/>	<hr/>
Total shareholders' equity	5,723	7,680
	<hr/>	<hr/>
Total liabilities and shareholders' equity	<u>\$ 8,699</u>	<u>\$ 9,422</u>

**Isoray, Inc. and Subsidiaries**  
**Consolidated Statements of Operations**  
(Dollars and shares in thousands, except for per-share amounts)

	<u>Three months ended June 30,</u>		<u>Twelve months ended June 30,</u>	
	<u>2020</u>	<u>2019</u>	<u>2020</u>	<u>2019</u>
Sales, net	\$ 2,279	\$ 1,924	\$ 9,680	\$ 7,314
Cost of sales	1,208	1,045	4,556	4,267
Gross profit	<u>1,071</u>	<u>879</u>	<u>5,124</u>	<u>3,047</u>
Operating expenses:				
Research and development				
Proprietary research and development	322	341	1,126	1,429
Collaboration arrangement, net of reimbursement	-	-	-	45
Total research and development	<u>322</u>	<u>341</u>	<u>1,126</u>	<u>1,474</u>
Sales and marketing	690	683	2,976	2,679
General and administrative	1,248	999	4,571	4,172
Gain on equipment disposals				(24)
Change in estimate of asset retirement obligation	-	-	(73)	-
Total operating expenses	<u>2,260</u>	<u>2,023</u>	<u>8,600</u>	<u>8,301</u>
Operating loss	<u>(1,189)</u>	<u>(1,144)</u>	<u>(3,476)</u>	<u>(5,254)</u>
Non-operating income:				
Interest income	1	49	30	108
Other income	-	-	-	2
Non-operating income, net	<u>1</u>	<u>49</u>	<u>30</u>	<u>110</u>
Net loss	(1,188)	(1,095)	(3,446)	(5,144)
Preferred stock dividends	(3)	(3)	(11)	(11)
Net loss applicable to common shareholders	<u>\$ (1,191)</u>	<u>\$ (1,098)</u>	<u>\$ (3,457)</u>	<u>\$ (5,155)</u>
Basic and diluted loss per share	<u>\$ (0.02)</u>	<u>\$ (0.02)</u>	<u>\$ (0.05)</u>	<u>\$ (0.08)</u>
Weighted average shares used in computing net loss per share:				
Basic and diluted	<u>68,075</u>	<u>67,357</u>	<u>67,601</u>	<u>67,042</u>